-transparent.png){kind=logo}
A correlation is reported between serum levels of triiodothyronine (S-T3) and thyroxine (S-T4) before treatment, as well as levels of thyroid antibodies before treatment, and the development of hypothyroidism following 131I therapy in 86 patients with hyperthyroidism. Patients with marked elevation of S-T3 or S-T4 had demonstrable antibodies to thyroid cytoplasmic antigen more often than those with normal or moderately elevated levels, and patients with markedly elevated levels of S-T3 also had a higher incidence of hypothyroidism after treatment. Patients with nodular thyroid glands and with markedly elevated levels of S-T3 required a larger number of 131I doses before no signs of hyperthyroidism persisted in comparison to those with moderately elevated levels.
G Lundell, and
L E Holm, and
J G Ljunggren, and
J Wasserman
November 1978,
Revista clinica espanola,
G Lundell, and
L E Holm, and
J G Ljunggren, and
J Wasserman
August 1983,
Metabolism: clinical and experimental,
G Lundell, and
L E Holm, and
J G Ljunggren, and
J Wasserman
April 2000,
MMW Fortschritte der Medizin,
G Lundell, and
L E Holm, and
J G Ljunggren, and
J Wasserman
January 1978,
Acta medica Scandinavica,
G Lundell, and
L E Holm, and
J G Ljunggren, and
J Wasserman
September 1980,
Journal of clinical pathology,
G Lundell, and
L E Holm, and
J G Ljunggren, and
J Wasserman
February 1977,
Kaku igaku. The Japanese journal of nuclear medicine,
G Lundell, and
L E Holm, and
J G Ljunggren, and
J Wasserman
July 2012,
European thyroid journal,
G Lundell, and
L E Holm, and
J G Ljunggren, and
J Wasserman
October 1973,
Acta radiologica: therapy, physics, biology,
G Lundell, and
L E Holm, and
J G Ljunggren, and
J Wasserman
February 1974,
Nihon Naibunpi Gakkai zasshi,
G Lundell, and
L E Holm, and
J G Ljunggren, and
J Wasserman
October 2013,
Current opinion in endocrinology, diabetes, and obesity,
